GRM7 and Parkinson disease: For example, while activation of mGluR4 has been shown to have neuroprotective effects in models of Parkinson’s disease, the role of other group III mGluR subtypes, such as mGluR7 and mGluR8, in the same pathological context is less clear [139–141].